{
    "clinical_study": {
        "@rank": "102537", 
        "arm_group": {
            "arm_group_label": "Brodalumab", 
            "arm_group_type": "Experimental", 
            "description": "open label, all subjects receive brodulamab"
        }, 
        "brief_summary": {
            "textblock": "This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in\n      subjects with moderate to severe plaque psoriasis.  It is designed to evaluate the effect of\n      brodalumab on midazolam PK in addition to assessing single dose PK of brodalumab in subjects\n      with moderate to severe plaque psoriasis."
        }, 
        "brief_title": "Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "Approximately 30 subjects will be enrolled into two groups. Group 1 consists of 20 subjects\n      and will receive 2 oral doses of midazolam and a single subcutaneous (SC) dose of\n      brodalumab.  Group 2 consists of 10 subjects and will receive a single SC dose of\n      brodalumab."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has had stable moderate to severe plaque psoriasis for at least 6 months\n\n          -  body mass index (BMI) between \u2265 18.0 and \u2264 38.0 kg/m2\n\n          -  body weight between \u2265 50 and \u2264 130 kg\n\n          -  no known history of active tuberculosis\n\n        Exclusion Criteria:\n\n          -  Female subjects who are lactating/breastfeeding\n\n          -  History or evidence of clinically significant disorder, condition or disease that, in\n             the opinion of the investigator or Amgen physician would pose a risk to subject\n             safety or interfere with the study evaluation, procedures or completion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937260", 
            "org_study_id": "20110184"
        }, 
        "intervention": {
            "arm_group_label": "Brodalumab", 
            "description": "Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.", 
            "intervention_name": "Brodalumab", 
            "intervention_type": "Drug", 
            "other_name": "AMG 827"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 15, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anaheim", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92801"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Irvine", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92697"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ocala", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34471"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78759"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herston", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4006"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adelaide", 
                        "country": "Australia", 
                        "state": "South Australia", 
                        "zip": "5000"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Prahran", 
                        "country": "Australia", 
                        "state": "Victoria", 
                        "zip": "3181"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Christchurch", 
                        "country": "New Zealand", 
                        "zip": "8011"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grafton, Auckland", 
                        "country": "New Zealand", 
                        "zip": "1010"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "New Zealand"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis", 
        "overall_contact": {
            "last_name": "Amgen Call Center", 
            "phone": "866-572-6436"
        }, 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "New Zealand: Medsafe"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The maximum observed concentration of midazolam after a single dose of brodalumab", 
                "safety_issue": "No", 
                "time_frame": "up to 22 days to 30 days"
            }, 
            {
                "measure": "The time to maximum concentration of midazolam after a single dose of brodalumab", 
                "safety_issue": "No", 
                "time_frame": "up to 22 days to 30 days"
            }, 
            {
                "measure": "The area under the serum-concentration curve of midazolam after a single dose of brodalumab", 
                "safety_issue": "No", 
                "time_frame": "up to 22 days to 30 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937260"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The number of treatment emergent adverse events per subject, including changes in vital signs, ECG, physical examinations, and laboratory safety parameters", 
                "safety_issue": "Yes", 
                "time_frame": "up to 22 to 30 days"
            }, 
            {
                "measure": "The number of subjects with anti-brodalumab antibodies after a single dose of brodalumab", 
                "safety_issue": "Yes", 
                "time_frame": "up to 22 to 30 days"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}